PharmacyEndocrinologyPharmacologyLabeling RegulationWomen's HealthDrug Safety MonitoringMedication Labeling RequirementsMenopause Hormone TherapyPeriodic Safety Update ReportingPost-marketing Safety SurveillanceSafety EvaluationDrug Labeling Safety UpdatesEstrogen ExposureEstrogen PharmacologyHormonal Contraceptive SafetyHormone SafetyReproductive Endocrine Drug SafetySafety Requirement Changes ManagementWarnings Labeling
The US Food and Drug Administration (FDA) is requiring new safety changes to the labels of all products containing estrogen alone or combined with progestin for use by postmenopausal women, warning that the drugs may slightly increase the risk of heart attack, stroke, breast cancer, and blood clots.